GLP-1 and GIP

Retatrutide: A New Triple-Agonist Obesity Therapy

admin / October 20, 2025

Retatrutide (LY3437943) is an experimental peptide drug that stimulates three hormone receptors – GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors – all involved in energy balance.

GLP-1 and GIP

Cagrilintide–Semaglutide Combination for Obesity and Fat Loss: Benefits and Risks

admin / October 17, 2025

Obesity is a major health challenge, and new treatments are emerging that combine semaglutide (a GLP-1 receptor agonist) with cagrilintide (a long-acting amylin analog). Semaglutide (sold as Wegovy/Ozempic) mimics the gut hormone GLP-1, which stimulates insulin, suppresses glucagon, slows stomach emptying and reduces appetite.

GLP-1 and GIP

Retatrutide: A New Triple-Agonist Obesity Therapy

Cagrilintide–Semaglutide Combination for Obesity and Fat Loss: Benefits and Risks

Follow Us

Disclaimer